Novo Nordisk’s core capabilities p to continue to defeat diabetes Engineering, formulating, developing and delivering protein- based treatments Efficient large-scale production of proteins Today: Oral solutions to differentiate from competition Today: The world’s largest producer of insulin and GLP-1 Tomorrow: Expand oral platforms and transformational medicines via Novo Nordisk stem cell platform Tomorrow: Expand capacity by completion of the US diabetes API facility and continued efficiency gains API: Active pharmaceutical ingredient
Download PDF file